FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Releases Bio-Thera Solutions FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with six observations from an inspection at Chinas Bio-Thera Solutions.

Commissioners National Priority Voucher for Bizengri

[ Price : $8.95]

FDA awards Partner Therapeutics a Commissioners National Priority Voucher for a new Bizengri indication.

Guidance on CMC Flexibility for Human CGTs

[ Price : $8.95]

FDA publishes a guidance explaining how the agency uses a flexible chemistry, manufacturing, and controls approach to help expedit...

FDA Meeting on AI pilot for Early-Stage Clinical Trials

[ Price : $8.95]

FDA hosts a virtual public meeting later this month to address industry questions tied to a planned pilot program exploring the us...

Guidance On Patient-Matched Guides for Orthopedic Implants

[ Price : $8.95]

FDA posts a new guidance detailing how manufacturers should design and submit regulatory applications for patient-matched guides u...

Expedite FDA Review of Breakthrough Mental Health Therapies: House Letter

[ Price : $8.95]

Some 30 bipartisan House members urge FDA to expedite its review of new mental health therapies.

FDA Hits Respilon Production for 5 CGMP Violations

[ Price : $8.95]

FDA warns Czechias Respilon Production about CGMP violations in its manufacturing of over-the-counter drugs.

Recent Accelerated Approval Path Changes Explained

[ Price : $8.95]

A Bioprocess Online guest column outlines recent changes to FDAs accelerated approval pathway that were made to address systemic f...

FDA, TransCelerate Collaborate on Streamlined Safety Data Collection

[ Price : $8.95]

TransCelerate reports on a 2025 tabletop exercise it convened with the CDER Center for Clinical Trial Innovation that focused on s...

FDA Blocks Publication of Vaccine Safety Studies

[ Price : $8.95]

New reporting reveals that FDA has withdrawn or blocked the publication of multiple internal studies supporting the safety of Covi...